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Defensins are endogenous antibiotics and regulators of inflammation, immunity and wound
repair. Their concentrations are substantially increased in bronchoalveolar lavage fluid
(BALF) of patients with infectious lung diseases. a-defensin (HAD) levels are also elevated
in patients with idiopathic pulmonary fibrosis (IPF) and correlated with the decline in
pulmonary function tests, suggesting the association of defensins with the pathogenesis of
interstitial lung diseases. The aim of this study was to determine the profile of defensins
in interstitial lung diseases. Serum and BALF levels of HAD and b-defensin 1 and 2 (HBD-1,
and -2) were measured by radioimmunoassay in 63 patients with interstitial lung diseases,
including idiopathic pulmonary alveolar proteinosis (PAP), IPF, nonspecific interstitial
pneumonia (NSIP), cryptogenic organizing pneumonia (COP) and pulmonary sarcoidosis,
and in 9 healthy volunteers as controls. Levels of HAD in BALF of patients with PAP were
significantly higher than those in controls and patients with COP and sarcoidosis. Serum
levels of HAD in all groups were significantly higher than those in controls. Levels of HBD-1
and -2 in BALF of patients with PAP were extremely high in all subjects. Serum levels of
HBD-1 were higher in all patient groups, with the exception of those with PAP, and those of
HBD-2 were also higher in patients with IPF and sarcoidosis, compared with controls. BALF
of PAP patients, but not IPF patients and controls, expressed antimicrobial activity against
Pseudomonas aeruginosa and Staphylococcus aureus. Our findings suggest different
kinetics of HAD and HBD-1 and -2 in serum and BALF of interstitial lung diseases and
that these antimicrobial peptides in the airway lumen may contribute to prevention of
bacterial airway infections in PAP.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The human airways are protected from invading micro-
organisms by a highly efficient innate immune system.
Antimicrobial peptides produced by inflammatory cells
and airway epithelial cells are key elements in this innate
immune system.1,2 A major subgroup of the antimicrobial
peptides is the family of defensins. Defensins are endogen-
ous antibiotics against Gram-positive and -negative bacter-
ia, fungi and enveloped viruses, which contribute to
host defense by disrupting the cytoplasmic membrane of
microorganisms.1 Recent studies indicate the importance of
these peptides as effectors of innate immunity by killing
microorganisms, but also as regulators of inflammation,
immunity and wound repair.1,2 In humans, six a-defensins
(HAD) have been recognized to date; four forms that
are exclusive to leukocytes [human neutrophil peptides
(HNPs)-1 to -4] and two others found in Paneth cells in
the small intestine.1,2 Because HNPs-1, -2 and -3 constitute
5–7% of the total protein content of the human neutrophil
and 30–50% of the total protein content of the azurophilic
granules, it is thought that they are the most abundant
antimicrobial proteins present in the neutrophil. On
the other hand, b-defensin (HBD), the second class of
defensin, was identified in bovine neutrophils and in
epithelial cells of bovine tongue and trachea.1 Human
HBD-1 was originally isolated from blood filtrate and is
expressed constitutively in epithelia of the urogenital tract,
trachea and respiratory tract.1 HBD-2, isolated from
psoriatic scale extracts, is expressed mainly in human skin,
trachea and lung and its expression increases in response to
infections and inflammatory mediators.1,2 HBD-1 and -2 are
currently thought to contribute to antimicrobial defense in
these tissues.
Previous reports have demonstrated the association
between these defensins and various infectious lung
diseases.3–7 Since defensins may also cause tissue injury,
modulate immunology, and contribute to repair pro-
cesses,1,2,8 the potential role of defensins in the pathogen-
esis of noninfectious lung diseases, including interstitial
lung diseases, is also of interest. In this context, an
enhanced antibacterial activity was found in bronchoalveo-
lar lavage fluid (BALF) material from patients with sarcoi-
dosis and this activity was present as several antibacterial
components, including HAD.9 We previously reported
that concentrations of HAD in plasma of patients with
idiopathic pulmonary fibrosis (IPF) were significantly higher
compared with control subjects, and correlated inversely
with pulmonary function tests.10 Positive immunohistochem-
ical staining of HAD was observed inside and outside
neutrophils in dense fibrotic lung areas obtained from these
patients.10 In acute respiratory distress syndrome (ARDS),
HAD levels of plasma and BALF were higher than in controls
and also correlated with the Lung Injury Score.11 These
findings suggest that defensins have clinical relevance to the
status of different interstitial lung diseases as well as
pulmonary infectious diseases. However, studies of the role
of these antimicrobial peptides, especially HBD, have not
been reported in interstitial lung diseases, including idio-
pathic pulmonary alveolar proteinosis (PAP), which is well
known for its association with susceptibility to pulmonary
infections.The aim of the present study was to determine the profile
of defensins in various interstitial lung diseases. Specifically,
we measured the serum and BALF concentrations of HAD,
HBD-1 and -2 by radioimmunoassay (RIA). The results showed
extremely high levels of these defensins in BALF of patients
with PAP, with antimicrobial activity against Pseudomonas
aeruginosa and Staphylococcus aureus.
Materials and methods
Sample preparation
Seventy-two subjects of this study were patients and healthy
volunteers enrolled in the Hospitals of Nagasaki University
School of Medicine. They included 7 patients with PAP
(4 males and 3 females; age 55 [42–68] years), 11 with IPF
(9 males and 2 females; age 62 [47–73] years), 15 with
idiopathic nonspecific interstitial pneumonia (NSIP) (8 males
and 7 females; age 57 [30–76] years), 7 with cryptogenic
organizing pneumonia (COP) (4 males and 3 females; age 62
[26–79] years), 23 with pulmonary sarcoidosis (7 males and
16 females; age 54 [25–78] years) and 9 healthy volunteers (5
males and 4 females; age 42 [21–66] years). None of the
enrolled patients had received steroids or other immuno-
suppressive therapy at the time of clinical sample collection.
Patients with cancer in any organ and those suspected to
have malignancy were excluded from the study. The
diagnosis was confirmed pathologically by surgical lung
biopsy in all patients with IPF, NSIP, and COP.12 Patients with
usual interstitial pneumonia, NSIP and bronchiolitis obliter-
ans organizing pneumonia associated with collagen vascular
diseases were excluded from the study. Sarcoidosis patients
were diagnosed using clinical, functional, radiographic and
histological criteria as previously reported.13 All healthy
volunteers had normal chest radiographs, were free of
symptoms and not taking any medications. The study
protocol was approved by the Human Ethics Review
Committees of Nagasaki University School of Medicine and
a signed consent form was obtained from each subject.
Bronchoalveolar lavage
After informed consent was obtained, BAL was performed
before treatment as previously described in Mukae et al.10
The bronchoscope was wedged into one of the segmental or
subsegmental bronchi of the right middle robe. An aliquot of
50ml sterile saline at body temperature was instilled
through the bronchoscope. The fluid was immediately
retrieved by gentle suction using a sterile syringe, and the
procedure was repeated three times. BALF was passed
through two sheets of gauze and then centrifuged at 500g
for 10min at 4 1C. After washing twice with phosphate-
buffered saline (PBS) free of calcium or magnesium (PBS,
Gibco, UK), the remaining cells were suspended in PBS
supplemented with 10% heat inactivated fetal calf serum
and counted using a hemocytometer. An aliquot was then
diluted to a concentration of 2 105 cells/ml, and 0.2ml of
cell suspension was spun down onto a glass slide at 1100 rpm
for 2min using a Cytospin 2 cytocentrifuge (Shandon
Instruments, Sewickley, PA). The remaining fluid was
centrifuged at 500g for 5min, and supernatant was stored
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fixed, and then stained using a May–Giemsa method. More
than 200 cells were identified using a photomicroscope. A
serum sample was also collected from each subject and
stored at 80 1C on the same day.
HAD assay
The concentration of HAD was measured by RIA established
in our laboratory.14 A diluted sample or standard peptide
solution (100 ml) was incubated for 24 h with 100 ml of
antiserum diluent (final dilution of 1/21,000). 125I-labeled
HAD solution (16,000 cpm in 100 ml) was then added, and the
mixture was incubated again for 24 h. In the next step,
normal rabbit serum and anti-rabbit IgG goat serum were
added, and the samples were stored for 16 h. Bound and free
ligands were separated by centrifugation. All procedures
were performed at 4 1C and duplicate assays were per-
formed. The antiserum recognized HNP-1, -2, and -3 equally
on a molar basis, so the RIA data were expressed as the sum
of HNPs1–3 and their precursor proteins, the presence of
which was confirmed by simultaneous measurements using
reverse phase high-performance liquid chromatography and
RIA.15 The respective intra- and interassay coefficients of
variation were 3.5% and 8% at 50% binding, respectively.
HBD assay
The concentrations of HBD-1 and 2 were also measured by
RIA established in our laboratory.16,17 Human HBD was radio-
iodinated by the lactoperoxidase method and the 125I-
labeled peptide was purified by RP-HPLC on a TSK ODS 120A
column (Tosoh Co.). The incubation buffer for RIA was 50mM
sodium phosphate (pH 7.4) containing 0.25% bovine serum
albumin (BSA) treated with N-ethylmaleimide, 80mM NaCl,
25mM EDTA 2Na, 0.05% NaN3, 0.1% Triton X-100, and 3.1%
dextran T-40. The diluted sample or a standard peptide
solution (100 ml) was incubated for 24 h with 100 ml of diluted
antiserum (final dilution of 1/460,000 and 1/4,200,000,
respectively). The tracer solution (16,000–18,000 cpm in
100 ml) was added and the mixture was incubated for 24 h,
after which normal rabbit serum and anti-rabbit IgG goat
serum were added, and the whole preparation was stored
for a further 16 h. Bound and free ligands were separated by
centrifugation. All procedures were performed at 4 1C and
the samples were assayed in duplicate.
Bactericidal assay
The antimicrobial activities of each BALF against P.
aeruginosa strain PAO-1 and S. aureus strain ATCC29213
were tested with colony count assay.18 Briefly, bacteria were
cultured overnight at 37 1C in Brain–Heart-Infusion (BHI,
Becton Dickinson Microbiology Systems, Cockeysville, MD).
An aliquot of this culture was transferred to the fresh BHI
and incubated for 3 h at 37 1C to obtain cells in logarithmic-
phase growth. Following the precipitation of bacteria by
centrifugation at 800g for 10min, samples were washed in
PBS and quantified spectrophotometrically by measuring
optical density at 620 nm. A culture volume containing
5 106 bacterial colony-forming units (CFU) was then addedto 500 ml of each BALF that had been filtered with Millexs-
LG 0.20-mm filter (Millipore, Cork, Ireland). The mixtures
were incubated for 4, 6, and 8 h in the experiments with P.
aeruginosa, and for 2, 4, 6, and 8 h in the experiments with
S. aureus at 37 1C, and then serially diluted and spread on
Mueller–Hinton II agar plates (Becton Dickinson Microbiology
Systems, Cockeysville, MD) for 18 h at 37 1C, after which the
colonies were counted.
Statistical analysis
Data were expressed as median (range). Differences
between groups were examined using one-way analysis of
variance. The posthoc test used Fisher’s PLSD test. The
Student’s t-test was used for comparisons between two
groups. A P-value o0.05 denoted the presence of a
statistically significant difference.
Results
BALF differential cell count
The BALF components of all groups are shown in Table 1. All
patient groups showed significantly higher total cell counts
and lower mean percentages of alveolar macrophages than
controls. The total cell count of patients with COP was also
increased significantly compared with those of IPF and
sarcoidosis patients. The mean percentage of lymphocytes
in BALF was significantly higher in patients with PAP, NSIP,
COP and sarcoidosis than in controls. The mean percentage
of eosinophils in BALF was significantly higher in patients
with PAP and IPF than in controls and patients with
sarcoidosis. There were no significant differences in the
mean percentage of neutrophils among the groups.
HAD and HBD levels in BALF and serum
Figure 1A shows the HAD levels in BALF measured by means
of RIA in the 72 study subjects. Levels of HAD in BALF of
patients with PAP (152 [1–327] pg/ml) were increased
significantly compared with controls (0 [0–66] pg/ml) and
patients with COP (16.5 [0–57] pg/ml) and sarcoidosis
(4.2 [0–161] pg/ml). BALF levels of HAD in patients with
IPF (7.7 [0–709] pg/ml) were significantly higher than
those in patients with sarcoidosis. BALF levels of HBD-1
and -2 in patients with PAP (905.9 [161.0–1509.8] pg/ml
and 56.5 [0–960] pg/ml, respectively) were significantly
higher than those in controls (50.2 [14.3–89.7] pg/ml and 0
[0–2.1] pg/ml, respectively) and other lung diseases (Fig. 2A
and 3A). Serum levels of HAD in all disease subjects were
significantly higher than in controls (Fig. 1B) and there were
no significant differences among all patient groups. Serum
levels of HBD-1 in patients with IPF, NSIP, COP and sarcoidosis
were increased significantly compared with controls, and
those with IPF and sarcoidosis were also increased signifi-
cantly compared with PAP (Fig. 2B). Serum levels of HBD-2 in
patients with IPF and sarcoidosis were significantly higher
than those in controls (Fig. 3B).
PAP patients have auto-antibodies against granulocyte-
macrophage colony-stimulating factor (GM-CSF)19 and an
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Table 1 General characteristics of BALF in patients with interstitial lung diseases.
Patients n Total cells 104 cells/ml Cell differential (%)
Macrophages Lymphocytes Neutrophils Eosinophils
Control 9 11.0 (2.0–37.0) 90.5 (85.2–96.1) 7.8 (2.6–11.5) 1.0 (0.1–4.7) 0.4 (0–2.3)
PAP 7 37.3 (26.5–93.4) 40.4 (16.9–69.4),z 40.4 (12.2–79.9),z 4.2 (0.1–20.1) 1.1 (0–33.4)
IPF 11 32.2 (10.8–72.0),y 78.4 (43.5–88.0),y 11.1 (2.9–29.9)y 5.6 (2.0–38.1) 3.6 (0–20.4)
NSIP 15 39.0(20.2–82.0) 69.3 (26.2–93.4) 25.9 (3.5–70.1),y 2.1 (0.5–41.4) 1.0 (0–6.4)z
COP 7 42.7 (26.9–148.8) 41.5 (7.3–80.9) 31.0 (15.2–92.7) 3.2 (0–13.4) 3.5 (0–16.5)
Sarcoidosis 23 29.3 (12.0–69.1),y 56.5 (7.6–88.4),z 39.1 (11.5–91.5),z 0.7 (0–43.4) 0.3 (0–5.9)z,y
Data are median (range). PAP: pulmonary alveolar proteinosis; IPF: idiopathic pulmonary fibrosis; NSIP: nonspecific interstitial
pneumonia; COP: cryptogenic organizing pneumonia.
Po0:05 versus control.
yPo0:05 versus COP.
zPo0:05 versus IPF.
yPo0:05 versus PAP.
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Figure 1 HAD concentrations in BALF (A) and serum (B) of
healthy volunteers (control) and patients with interstitial lung
diseases. PAP: idiopathic pulmonary proteinosis; IPF: idiopathic
pulmonary fibrosis; NSIP: idiopathic nonspecific interstitial
pneumonia; COP: cryptogenic organizing pneumonia.
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Figure 2 HBD-1 concentrations in BALF (A) and serum (B) of
controls and patients with interstitial lung diseases.
H. Mukae et al.718elevated level of surfactant protein (SP)-A is found in their
serum and BALF.20 These auto-antibodies and proteins have
a possibility of interfering with these immunoassays, so we
measured the levels of these defensins after mixing theequal volume of BALF from controls and PAP patients. The
total of three PAP patients and healthy volunteers were
recruited to this experiment and the BALF mixtures
were analyzed. The average levels of HAD and HBD-1, 2
were 682.0, 339.8, and 431.6 pg/ml, respectively, which are
almost equal to the mean of defensin levels acquired from
independent measurement of BALF from each of the PAP
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Figure 3 HBD-2 concentrations in BALF (A) and serum (B) of
controls and patients with interstitial lung diseases.
1.E+05
1.E+06
1.E+07
1.E+08
1.E+09
1.E+10
2 4 6 8
Time (h)
CF
U
/m
l
1.E+05
1.E+06
1.E+07
1.E+08
1.E+09
1.E+10
4 6 8
Time (h)
CF
U
/m
l
∗
∗
(A)
(B)
Figure 4 The antimicrobial activities of BALF of patients with
PAP, IPF and healthy volunteers against P. aeruginosa (A) and S.
aureus (B). Closed circles, PAP; closed squares, IPF; open
circles, healthy volunteers; open squares, saline. nPo0:05
compared with each group.
Defensins in PAP 719patients and controls. In addition, using these RIA systems,
serial diluted solutions of SP-A (kindly provided by Prof. H.
Takahashi and Dr. H. Chiba in Third Department of Internal
Medicine, Sapporo Medical University School of Medicine)
and rat anti-human GM-CSF antibody (Beckman Coulter,
Inc., Fullerton, CA) (0–12.8 mg/ml) were measured the
defensin levels and the levels of these defensins in all
samples were lower than detection limits. These indicate
that these auto-antibodies and SP-A in PAP patients might
not interfere with these RIA.
Antimicrobial activity of BALF
We performed a colony count assay using the BALF obtained
from five healthy controls, six patients with PAP and six with
IPF. The BALF from patients with PAP inhibited bacterial
growth of P. aeruginosa (4-h incubation) and S. aureus (2-h
incubation) compared with the BALF from healthy controls
and patients with IPF (Fig. 4).
Discussion
The major finding of the present study was that there was a
distinct profile of serum and BALF levels of HAD and HBD
among different interstitial lung diseases. In addition, there
were no significant differences in the serum levels of HBD-1and -2 between PAP patients and controls, while the BALF of
patients with PAP had extremely high levels of these
defensins and also showed antimicrobial activity against
P. aeruginosa and S. aureus.
PAP is a rare auto-immune lung disease characterized by
abnormal surfactant accumulation within alveolar macro-
phages, and circulating auto-antibodies against GM-CSF
resulting in functional GM-CSF deficiency.19 Surfactant lipids
and proteins are synthesized, stored, and secreted into the
alveoli by alveolar type II epithelial cells.19 We initially
hypothesized that HBD levels might be elevated in patients
with PAP because HBD-2 was detected mainly in alveolar
type II cells in the lung by our previous immunohistochem-
ical study.7 In the present study, the levels of these
defensins, especially HBD, in BALF obtained from PAP
patients were extremely high and increased significantly
compared with controls and patients with other interstitial
lung diseases. In addition, the BALF levels of HBD-1 and -2 in
PAP were also higher than previously reported levels in
diffuse panbronchiolitis (HBD-1 264.1761.0 pg/ml and HBD-
2 71.5728.7 pg/ml),7 which is a progressive disease
characterized by frequent episodes of superimposed infec-
tion by P. aeruginosa. An important feature of PAP is the
associated susceptibility to pulmonary infections, some-
times with opportunistic organisms. Primary and cultured
alveolar macrophages from mice with targeted disruption of
the gene encoding GM-CSF have defects in cellular adhesion,
expression of pathogen-recognition receptors, phagocytosis,
superoxide production, microbial killing and secretion of
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may account for the susceptibility to infections in this
disease. In the present study, extremely high levels of both
HAD and HBD in BALF were observed in PAP. Although
alveolar macrophages are known to be cell source of these
defensins,21 the elevation of defensins in BALF of PAP
patients may be due to reduced clearance by alveolar
macrophage dysfunction. In this study, an antimicrobial
activity against P. aeruginosa and S. aureus was also
observed in the BALF of patients with PAP, but not IPF and
controls. Since defensins are the most prominent antimi-
crobial factors in airway surface fluid,22 antimicrobial
peptides including defensins in the lung may contribute to
prevention of bacterial infection in the lung of patients with
PAP. In this context, SP-A, has also bactericidal activity,23 is
known to be elevated in BALF of PAP patients,20 so SP-A may
also contribute to this BALF activity.
Meanwhile, the serum levels of HBD in PAP patients were
similar to control subjects. On light-microscopic examina-
tion, the architecture of the PAP lung parenchyma is
preserved and the walls of transitional airways and alveoli
are usually normal.19 Therefore, the HBD secreted into the
airspace may not influx into the bloodstream in PAP. In this
context, the levels of KL-6, a mucin-like high-molecular
weight glycoprotein, were found to be elevated in patients
with various interstitial lung diseases, especially PAP.24 In
PAP, the origin of the elevated KL-6 is suggested to be
proliferating type II pneumocytes, like HBD-2. Markedly high
levels of KL-6 are found in serum as well as in BALF in PAP
patients, suggesting that KL-6 produced abundantly by type
II pneumocytes leaks into the bloodstream from the
alveoli.24 Defensins are suggested to leak into the circula-
tion from the alveoli more easily than KL-6 because they are
small peptides with a molecular mass of 3.5–5 kDa. Further
investigations are required into the alveolar-capillary
barrier and the clearance of these molecules in this disease.
Levels of HAD, mainly localized in neutrophils, were also
increased significantly in BALF of patients with PAP
compared with controls and patients with COP and sarcoi-
dosis. Cell analysis of BALF from PAP patients revealed a
significantly increased percentage of lymphocytes, but not
neutrophils (Table 1), consistent with a previous report.25
However, the absolute number of neutrophils in BALF was
increased significantly due to a significantly higher total cell
count in BALF from PAP patients. Therefore, we suggest that
the origin of HAD in the PAP lung is neutrophils in the airway
lumen, and that the elevation of HAD in BALF of PAP patients
may be due to reduced clearance, like other surfactant
lipids and proteins.19 Serum levels of HAD in all patient
groups were significantly higher than those in controls. HAD
are secreted from neutrophil precursor cells in the bone
marrow into the plasma as pro-defensins, where they make
up 25% of the plasma HAD molecules in normal subjects.15 In
our previous studies, the rise of plasma HAD levels in
patients with infectious lung diseases was mainly derived
from activated neutrophil precursor cells in the bone
marrow.6,26 Therefore, we suggest that mediators released
from inflammatory cells and epithelial cells in the lung of
interstitial lung diseases may also directly stimulate the
bone marrow to enhance the release of HAD from precursor
cells in the bone marrow into the circulation, as in infectious
lung diseases.Serum levels of HBD-2 in patients with IPF and sarcoidosis
were significantly higher than those in controls. In addition,
serum levels of HBD-1 in these patients were significantly
higher than those in controls and patients with PAP, while
there were no significant differences in BALF HBD levels
between controls and IPF and sarcoidosis. In IPF patients, we
previously reported that levels of HAD in plasma were
significantly higher compared with control subjects and
reflected the clinical course and pulmonary function tests.10
These results suggest that serum but not BALF levels of HBD
as well as HAD may be associated with the pathogenesis of
sarcoidosis and IPF, similar to infectious lung diseases.5,7
In summary, we have demonstrated the presence of
differential profiles of serum and BALF defensins in different
interstitial lung diseases. Our results suggest that patterns
of defensin elevation in BALF may be helpful in distinguish-
ing PAP from other lung diseases and that these antimicro-
bial peptides in airway may contribute to prevention of
bacterial infection in PAP.Acknowledgments
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